UK fines Advanz £100m for raising thyroid drug price tenfold
pharmaphorum
JULY 29, 2021
The UK has levied another big fine for anticompetitive activity in the pharma market in a fortnight, with Advanz Pharma and former owners on the hook for more than £100 million ($140 million) after increasing the price of a thyroid disease drug by 1,110% over an eight-year period. ” Advanz itself was directly fined £40.9
Let's personalize your content